- Home
- GIGM vs PPBT Comparison
GIGM vs PPBT Comparison
Compare GIGM & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | PPBT |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | Taiwan | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 2.4M |
| IPO Year | 2002 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GIGM | PPBT |
|---|---|---|
| Price | $1.43 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 4.2K | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.41 |
| 52 Week High | $1.72 | $5.18 |
Technical Indicators
Market Signals| Indicator | GIGM | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 41.84 |
| Support Level | $1.37 | $1.39 |
| Resistance Level | $1.54 | $1.85 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 89.44 | 27.36 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. The only segment and principal business of the company is digital entertainment service business, that operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. The company operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown. The company generates majority revenue from Taiwan.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.